KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
December 13 2021 - 7:30AM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, today announced that it has been named the 2021 David J.
Gury Company of the Year by BioFlorida. The award, presented during
the 2021 BioFlorida Annual Conference, is in recognition of the
U.S. Food and Drug Administration’s (FDA) approval of AZSTARYS® for
the treatment of attention deficit hyperactivity disorder (ADHD) in
patients 6 years and older, and other important milestones achieved
by KemPharm over the past year. Corium, Inc. is leading all
commercialization efforts for AZSTARYS in the U.S.
The David J. Gury Company of the Year Award
recognizes a Florida-based life sciences company that has
demonstrated significant, quantifiable achievements in financing
deals, partnering agreements, research discoveries, grants,
clinical trials, approvals, product development or
commercialization milestones. Winners must also
demonstrate a history of service to the BioFlorida mission to
advance the life sciences industry in Florida. BioFlorida
represents over 6,700 establishments and research organizations in
the biopharmaceuticals, medical technology, health IT and
bio-agriculture sectors.
“We're excited to recognize KemPharm as the
BioFlorida’s 2021 David J. Gury Company of the Year and celebrate
their growth and efforts with their recent FDA approval of an
innovative new ADHD therapy and the potential it holds to meet the
unmet needs of this patient population,” said Nancy K. Bryan,
President and CEO of BioFlorida. “The KemPharm team has
a personal passion for ADHD understanding both what it is like to
live with it and parent those living with ADHD. The team uses this
passion to continue to push for better products for patients and
are poised for continued success in the future.”
KemPharm harnesses its LAT® technology to
develop proprietary prodrugs for serious medical conditions. 2021
was highlighted by Corium’s U.S. commercial launch of AZSTARYS®, a
new once-daily treatment for ADHD in patents age six years and
older. Additionally, during 2021, KemPharm was able to complete an
extensive financial restructuring, which enabled the company to
eliminate all of its debt, add significant cash to its balance
sheet, and re-emerge as a Nasdaq-listed company. Most
recently, KemPharm announced the uplisting of the company’s stock
to The Nasdaq Global Select Market, which is recognized as having
the highest initial listing standards of any exchange in the world
and is considered a mark of achievement and stature for qualified
companies.
“2021 has been a year of significant achievement
for KemPharm, and the company is now well positioned for continued
growth in 2022 and beyond,” said Travis Mickle, Ph.D., President
and Chief Executive Officer of KemPharm. “The launch of
AZSTARYS and approval of the drug by the FDA earlier this year were
seminal events in KemPharm’s history, validating the company’s LAT
technology and approach to prodrug development. Dovetailing this
success was the revitalization of KemPharm’s business and finances,
which has resulted in the company having clean balance sheet and
strong cash position.”
Dr. Mickle concluded, “I would like to express
my sincerest gratitude to BioFlorida for naming KemPharm the 2021
David J. Gury Company of the Year. This is a tremendous honor for
our company, especially given how much the Florida biotechnology
industry, as championed by BioFlorida, has grown over the past
several years.”
About
AZSTARYS®:
AZSTARYS is an FDA-approved, once-daily product
for the treatment of attention deficit hyperactivity disorder
(ADHD) in patients age six years or older. AZSTARYS consists of
SDX, KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated
with immediate release d-MPH. Corium, Inc. is leading all
commercialization efforts for AZSTARYS in the U.S.
The complete approved prescribing information
for AZSTARYS may be downloaded in PDF format
here:https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Final_20210302.pdf
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). In addition, the
U.S. Food and Drug Administration (FDA) has approved AZSTARYS®, a
once-daily treatment for ADHD in patents age six years and older
containing KemPharm’s prodrug, serdexmethylphenidate (SDX), and
APADAZ®, an immediate-release combination product containing
benzhydrocodone, KemPharm’s prodrug of hydrocodone, and
acetaminophen. For more information on KemPharm and its pipeline of
prodrug product candidates visit www.kempharm.com or connect with
us on Twitter, LinkedIn, Facebook and YouTube.
Caution Concerning Forward Looking
Statements:
This press release may contain forward-looking
statements made in reliance upon the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include all statements that do not
relate solely to historical or current facts and can be identified
by the use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the continued commercialization of AZSTARYS® and the
further development of KemPharm’s pipeline of product candidates,
are based on information currently available to KemPharm and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning KemPharm’s business are described in detail
in KemPharm’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2021, and KemPharm’s other filings with the
Securities and Exchange Commission. KemPharm is under no obligation
to, and expressly disclaims any such obligation to, update or alter
its forward-looking statements, whether as a result of new
information, future events or otherwise.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024